Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Surg Innov ; 29(6): 769-780, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-35331068

RESUMO

BACKGROUND: We developed a multi-resolution foveated laparoscope (MRFL) to improve situational awareness in laparoscopic surgery. We assessed surgeon objective task performance and subjective attitudes with MRFL when used for box trainer tasks and porcine surgery. METHODS: The MRFL simultaneously obtains a wide-angle view and a magnified view. The 2 images are displayed simultaneously. 6 urologists and 2 general surgeons performed box trainer and porcine surgery tasks with the MRFL and a standard laparoscope. Task time, use of display options, and subjective assessments were obtained. RESULTS: Subjectively, surgeons rated situational awareness, depth perception, and instrument interference as comparable between the prototype MRFL and laparoscope for trainer tasks. For porcine surgery, the MRFL was rated as having less interference than the standard laparoscope. The image quality of the MRFL was rated interior to the standard laparoscope. Participants found the different viewing modes useful for different roles and reported that they would likely use the MRFL for conventional laparoscopic and robotic surgery. Objectively, box trainer task time was comparable for 2 of 3 tasks with the remaining task shorter for the standard laparoscope. Porcine nephrectomy and oophorectomy were feasible with the prototype MRFL, although nephrectomy task time was significantly longer than traditional laparoscopy. CONCLUSIONS: The MRFL demonstrated feasibility for performing complex surgery. Surgeons had favorable attitudes toward its features and likelihood to use the device if available. Users utilized different view types for different tasks. Longer MRFL task times were attributed to poorer image quality of the prototype.


Assuntos
Laparoscopia , Procedimentos Cirúrgicos Robóticos , Cirurgiões , Suínos , Animais , Humanos , Laparoscópios , Análise e Desempenho de Tarefas , Competência Clínica
2.
Cancer Rep (Hoboken) ; 4(3): e1345, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-33635593

RESUMO

BACKGROUND: Febrile neutropenia is a serious complication of chemotherapy. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score identifies patients at low risk of serious complications. Outpatient management programs have been successfully piloted in other Australian metropolitan cancer centers. AIM: To assess current management of febrile neutropenia at our regional cancer center and determine potential impacts of an outpatient management program. METHOD: We performed a retrospective review of medical records for all patients admitted at our regional institution with febrile neutropenia between 1 January 2016, and 31 December 2018. We collected information regarding patient characteristics, determined the MASCC risk index score, and if low risk, we determined the eligibility for outpatient care and potential reduction in length of stay and cost benefit. RESULTS: A total of 98 hospital admissions were identified. Of these, 66 had a MASCC low-risk index score. Fifty-eight patients met the eligibility criteria for outpatient management. Seventy-one percent were female. The most common tumor type was breast cancer. Forty-eight percent were treated with curative intent. The median length of stay was 3 days. The median potential reduction in length of stay for each admission was 2 days. The total potential reduction in length of stay was 198 days. No admission resulted in serious complications. CONCLUSION: This review demonstrates a significant number of hospital admission days can be avoided. We intend to conduct a prospective pilot study at our center to institute an outpatient management program for such low-risk patients with potential reduction in hospital length of stay. This will have significant implications on health resource usage, service provision planning, and patient quality of life.


Assuntos
Assistência Ambulatorial/métodos , Antineoplásicos/efeitos adversos , Neutropenia Febril/terapia , Tempo de Internação/estatística & dados numéricos , Neoplasias/tratamento farmacológico , Assistência Ambulatorial/estatística & dados numéricos , Institutos de Câncer/economia , Institutos de Câncer/estatística & dados numéricos , Análise Custo-Benefício , Neutropenia Febril/induzido quimicamente , Neutropenia Febril/diagnóstico , Neutropenia Febril/economia , Feminino , Humanos , Tempo de Internação/economia , Masculino , Neoplasias/economia , Neoplasias/psicologia , Projetos Piloto , Estudos Prospectivos , Qualidade de Vida , Programas Médicos Regionais/economia , Programas Médicos Regionais/estatística & dados numéricos , Estudos Retrospectivos , Medição de Risco/estatística & dados numéricos , Fatores de Risco , Índice de Gravidade de Doença
3.
J Urol ; 194(2): 378-85, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25711194

RESUMO

PURPOSE: We assessed survival after radical prostatectomy, intensity modulated radiation therapy or conformal radiation therapy vs no local therapy for metastatic prostate cancer adjusting for patient comorbidity, androgen deprivation therapy and other factors. MATERIALS AND METHODS: We identified men 66 years old or older with metastatic prostate cancer treated with radical prostatectomy, intensity modulated radiation therapy, conformal radiation therapy or no local therapy in the SEER-Medicare linked database from 2004 to 2009. Multivariable Cox proportional hazards models before and after inverse propensity score weighting were used to assess all cause and prostate cancer specific mortality. Competing risk regression analysis was done to assess prostate cancer specific mortality. RESULTS: Of 4,069 men with metastatic prostate cancer radical prostatectomy in 47, intensity modulated radiation therapy in 88 and conformal radiation therapy in 107 were selected as local therapy vs no local therapy in 3,827. Radical prostatectomy was associated with a 52% decrease (HR 0.48, 95% CI 0.27-0.85) in the risk of prostate cancer specific mortality after adjusting for sociodemographics, primary tumor characteristics, comorbidity, androgen deprivation therapy and bone radiation within 6 months of diagnosis. Intensity modulated radiation therapy was associated with a 62% decrease (HR 0.38, 95% CI 0.24-0.61) in the risk of prostate specific cancer specific mortality. Conformal radiation therapy was not associated with improved survival compared to no local therapy. Propensity score weighting yielded comparable results. Competing risk analysis revealed a 42% and 57% decrease (SHR 0.58, 95% CI 0.35-0.95 and SHR 0.43, 95% CI 0.27-0.68, respectively) in the risk of prostate cancer specific mortality for radical prostatectomy and intensity modulated radiation therapy. CONCLUSIONS: Local therapy with radical prostatectomy and intensity modulated radiation therapy but not with conformal radiation therapy was associated with a survival benefit in men with metastatic prostate cancer. This finding warrants prospective evaluation in clinical trials.


Assuntos
Medicare , Prostatectomia/métodos , Neoplasias da Próstata/terapia , Medição de Risco , Programa de SEER , Idoso , Braquiterapia , Humanos , Masculino , Pessoa de Meia-Idade , Pontuação de Propensão , Modelos de Riscos Proporcionais , Estudos Prospectivos , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/epidemiologia , Neoplasias da Próstata/mortalidade , Neoplasias da Próstata/secundário , Radioterapia Conformacional , Fatores de Risco , Taxa de Sobrevida/tendências , Estados Unidos/epidemiologia
4.
Altern Lab Anim ; 37 Suppl 1: 19-27, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19807200

RESUMO

While the duration and size of human clinical trials may be difficult to reduce, there are several parameters in pre-clinical vaccine development that may be possible to further optimise. By increasing the accuracy of the models used for pre-clinical vaccine testing, it should be possible to increase the probability that any particular vaccine candidate will be successful in human trials. In addition, an improved model will allow the collection of increasingly more-informative data in pre-clinical tests, thus aiding the rational design and formulation of candidates entered into clinical evaluation. An acceleration and increase in sophistication of pre-clinical vaccine development will thus require the advent of more physiologically-accurate models of the human immune system, coupled with substantial advances in the mechanistic understanding of vaccine efficacy, achieved by using this model. We believe the best viable option available is to use human cells and/or tissues in a functional in vitro model of human physiology. Not only will this more accurately model human diseases, it will also eliminate any ethical, moral and scientific issues involved with use of live humans and animals. An in vitro model, termed "MIMIC" (Modular IMmune In vitro Construct), was designed and developed to reflect the human immune system in a well-based format. The MIMIC System is a laboratory-based methodology that replicates the human immune system response. It is highly automated, and can be used to simulate a clinical trial for a diverse population, without putting human subjects at risk. The MIMIC System uses the circulating immune cells of individual donors to recapitulate each individual human immune response by maintaining the autonomy of the donor. Thus, an in vitro test system has been created that is functionally equivalent to the donor's own immune system and is designed to respond in a similar manner to the in vivo response.


Assuntos
Alternativas aos Testes com Animais , Endotélio Vascular/imunologia , Leucócitos/imunologia , Tecido Linfoide/imunologia , Modelos Imunológicos , Vacinas/imunologia , Animais , Anticorpos Antibacterianos/biossíntese , Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/administração & dosagem , Antígenos de Bactérias/imunologia , Ensaios Clínicos como Assunto , Avaliação Pré-Clínica de Medicamentos , Ensaios de Triagem em Larga Escala , Humanos , Toxina Tetânica/administração & dosagem , Toxina Tetânica/imunologia
5.
Arch Surg ; 142(12): 1177-81; discussion 1181, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18086984

RESUMO

HYPOTHESIS: Patient safety and satisfaction are adversely affected when robotic videoconferencing (telerounding) is used in the postoperative setting. DESIGN: Randomized controlled trial. SETTING: Three academic institutions. PATIENTS: A total of 270 adults undergoing a urologic procedure requiring a hospital stay of 24 to 72 hours were randomized to receive either traditional bedside rounds or robotic telerounds. MAIN OUTCOME MEASURES: The primary outcome measure was postoperative patient morbidity. Secondary outcomes were patient-reported satisfaction and hospital length of stay. Other variables assessed included demographics, procedure, operative time, estimated blood loss, and mortality. Patients also completed a validated satisfaction instrument 2 weeks after hospital discharge. RESULTS: Patients were equally distributed based on the baseline demographic and operative measures. Morbidity rates were similar between the study arms (standard rounds vs telerounds: 16% vs 13%; P = .64). Length of stay was similar in both arms (standard rounds vs telerounds: 2.8 vs 2.8 days; P = .94). In addition, patient satisfaction was equivalently high in both arms of the study. CONCLUSIONS: Robotic telerounds matched the performance of standard bedside rounds after urologic surgical procedures. Virtual visits did not result in missed or increased postoperative complications. Hospital length of stay and ratings of hospital satisfaction were on par with those for traditional rounding.


Assuntos
Robótica , Telemedicina , Procedimentos Cirúrgicos Urológicos , Endoscopia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Período Pós-Operatório , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA